None listed
Conditions
Interventions
Drug : This study is a randomized, double-blind, placebo-controlled, prospective clinical trial designed to evaluate the effect of flumazenil on postoperative quality of recovery (Quality of Recovery)
Sponsors
Chonnam National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients scheduled to undergo laparoscopic cholecystectomy under general anesthesia Classified as American Society of Anesthesiologists (ASA) Physical Status I, II, or III Aged 65 years or older and younger than 80 years at the time of surgery Provides written informed consent after receiving a full explanation of the study
Exclusion criteria
Exclusion criteria: Known hypersensitivity or contraindications to study drugs (e.g., remimazolam, flumazenil) Body Mass Index (BMI) = 35 Abnormal liver function (e.g., liver enzymes = 5 times the upper normal limit) or renal impairment (eGFR < 45 mL/min/1.73m²) Current use of psychiatric medications Inability to understand or complete questionnaires due to illiteracy or cognitive impairment Refusal to participate in the study or withdrawal of informed consent Any condition deemed by the investigator to pose unacceptable risk or interfere with study procedures
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Cognitive Function (K-MMSE Score) | — |
Primary
| Measure | Time frame |
|---|---|
| Quality of Recovery (QoR-15K Score) | — |
Countries
Korea, Republic of
Contacts
Public ContactJoonsuk Bom
Chonnam National University Hospital
Outcome results
None listed